Shandong Jiantong Biotechnology

Shandong Jiantong Biotechnology is a Chinese biopharmaceutical company specializing in the development and industrialization of recombinant human serum albumin (rHSA). Founded in 2016 and based in Tai'an, Shandong, the company utilizes advanced genetic engineering and fermentation technologies to produce high-purity rHSA as a safe and sustainable alternative to blood-derived albumin. Its lead program, Gene F616, is currently in Phase 1 clinical trials in China for the treatment of hypoalbuminemia. The company operates through strategic partnerships with the Chinese Academy of Sciences, China CDC, and the Japan JNC Group to address the global shortage of human serum albumin. Recognized as a National High-tech Enterprise, Shandong Jiantong is a key participant in regional biopharmaceutical innovation initiatives.